Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
9 Cards in this Set
- Front
- Back
|
Peak incidence and chromosomes involved of AML in 1. Post radiation 2. Post Alkylating agents 3. Post TI II |
1. 5-7 years 2. 4-6 years (Chromosomes 5,7) 3. 1-3 years (Chromosomes 11) |
|
|
Seven categories of AML |
AML with recurrent genetic abnormalities AML with MDS related changes Therapy related AML AML NOS Myeloid sarcoma Myeloid proliferation related to Downs Blastic plasmacytoid dendritic cell neoplasm |
|
|
Seven sub categories and two provisional entities in AML with recurrent genetic abnormalities |
|
|
|
Nine subcategories of AML NOS |
|
|
|
CD markers that are 1. Myeloid specific 2. Platelet specific |
1. CD13, CD117 2. CD 41, CD61 |
|
|
Cytogenetics linked to AML morphology 1. APL 2. AML with eosinophils 3. AML w slender auer rods and eosinophils and expression of CD19 4. Monocytic features 5. Myeloid sarcoma |
1. t(15,17) 2. inv(16) 3. t(8,21) 4. t(9,11) 5. t(8,21) |
|
|
Chromosomal features with 1. Good prognosis 2. Bad prognosis |
1. t(8,21), inv(16), t(15,17), miR-181a overexpression, NPM1, CEBPA 2. complex karyotype, monosomal karyotype, t(6,9), inv(3), del(7), FLT3ITD |
|
|
AML with Monocytic and those with 11q abnormalities have clinical features of |
Gingival, skin, soft tissue, meningeal infiltration with leukemic blasts |
|
|
Medication to be used in CBF AML |
Gemtuzumab ozogamycin (CD33 - calicheamicin) |
